Synthesis and structure–activity relationship of diarylamide derivatives as selective inhibitors of the proliferation of human coronary artery smooth muscle cells
摘要:
A series of diarylamide derivatives were synthesized and evaluated for their inhibitory activities against human coronary artery smooth muscle cells (SMCs) and human coronary artery endothelial cells (ECs). Compound 2w was superior to the lead compound, Tranilast, in terms of the potency of the activity and cell selectivity. (C) 2001 Elsevier Science Ltd. All rights reserved.
A new protocol for the synthesis of primary, secondary and tertiary anthranilamides utilizing N-(2-aminoarylacyl)benzotriazoles
作者:Nevin Kanışkan、Şule Kökten、İlhami Çelik
DOI:10.3998/ark.5550190.0013.818
日期:——
A convenient route for efficient conversion of unprotected anthranilic acids into the corresponding N-(2-aminoarylacyl)benzotrazoles is described. N-(2-Aminoarylacyl)benzotrazoles have been successfully used to synthesize primary, secondary and tertiaryanthranilamides in high yields (71-96%).
[EN] HETEROAROMATIC QUINOLINE-BASED COMPOUNDS<br/>[FR] COMPOSÉS HÉTÉRO-AROMATIQUES À BASE DE QUINOLINE
申请人:PFIZER PROD INC
公开号:WO2008020302A2
公开(公告)日:2008-02-21
[EN] The invention pertains to heteroaromatic compounds that serve as effective phosphodiesterase (PDE) inhibitors. The invention also relates to compounds which are selective inhibitors of PDE10. The invention further relates to intermediates for preparation of such compounds; pharmaceutical compositions comprising such compounds; and the use of such compounds in methods for treating certain central nervous system (CNS) or other disorders. The invention relates also to methods for treating neurodegenerative and psychiatric disorders, for example psychosis and disorders comprising deficient cognition as a symptom. [FR] La présente invention concerne des composés hétéro-aromatiques servant d'inhibiteurs efficaces de phosphodiestérase (PDE). L'invention conerne également des composés qui sont des inhibiteurs sélectifs de PDE10. L'invention concerne en outre des intermédiaires pour la préparation de tels composés, des compositions pharmaceutiques comprenant de tels composés, ainsi que l'utilisation de tels composés dans des procédés de traitement de certains troubles du système nerveux central (CNS) ou autres. L'invention concerne de plus des procédés de traitement de troubles neurodégénératifs et psychiatriques, par exemple la psychose et des troubles ayant comme symptôme un déficit de cognition.